Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of triptolide in preparation of medicine for preventing and/or treating liver diseases

A technology of triptolide and a drug is applied in the field of medicine to achieve the effects of exact treatment effect, delaying liver steatosis, and reducing serum liver enzyme levels

Pending Publication Date: 2021-10-22
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are few reports on the use of triptolide in the prevention and treatment of liver diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of triptolide in preparation of medicine for preventing and/or treating liver diseases
  • Application of triptolide in preparation of medicine for preventing and/or treating liver diseases
  • Application of triptolide in preparation of medicine for preventing and/or treating liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 The effect of triptolide on delaying liver fibrosis

[0033] Experimental animals: wild C57BL / 6J mice. At least 1 week before the experiment, the rats were fed with a standardized experimental diet in a constant temperature environment, with unlimited drinking water.

[0034] Animal grouping: 24 mice were divided into 3 groups: ① 8 mice in the control diet group; ② 8 mice in the methionine-choline-deficient diet (MCD) group; ③ 8 mice in the triptolide treatment group (50 μg / kg / d).

[0035] Modeling method: 8-week-old C57BL / 6J male mice were fed with MCD feed for 5 weeks to establish a non-alcoholic hepatitis model. After 5 weeks, heart blood and liver tissue were collected from mice in each group.

[0036] Administration method: 50 μg / kg / d triptolide was administered by intraperitoneal injection after 3 weeks of feeding with MCD feed for 14 consecutive days; the MCD model group was fed with the same dose of normal saline at the same time after modeling.

[...

Embodiment 2

[0047] Example 2 The effect of triptolide in treating non-alcoholic fatty liver disease

[0048] Experimental animals: SPF grade male leptin receptor gene deficient (db / db) mice. At least 1 week before the experiment, the rats were fed with a standardized experimental diet in a constant temperature environment, with unlimited drinking water.

[0049] Grouping of animals: 24 mice were divided into 3 groups: ① 8 mice in the normal control group; ② 8 mice in the non-alcoholic fatty liver disease model group; ③ 8 mice in the triptolide treatment group.

[0050] Modeling method: db / db mice will spontaneously develop non-alcoholic fatty liver disease due to leptin receptor gene defect. After 18 weeks, the mice were sacrificed, blood was collected from the abdominal aorta, and the liver tissue was retained.

[0051] Administration method: 50 μg / kg triptolide was administered intravenously when db / db mice were 8 weeks old, and continued for 10 weeks; the model group was intravenousl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of triptolide in preparation of a medicine for preventing and / or treating liver diseases, and particularly relates to application of triptolide or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease or liver fibrosis. Experimental results show that the triptolide can obviously reduce the serum liver enzyme level, also has the effect of delaying fatty degeneration, inflammation and fibrosis of the liver, can obviously reduce the expression quantity of fibrosis-related proteins such as alpha-SMA, collagen I and fibronectin, has an exact treatment effect on the non-alcoholic fatty liver disease, and provides a new choice for clinical medication.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of triptolide in the preparation of medicines for preventing and / or treating liver diseases. Background technique [0002] Non-alcoholic fatty liver disease refers to liver metabolic diseases caused by long-term heavy drinking and other clear liver damage factors, and the accumulation of triglyceride-based lipids in liver cells is a pathological change. Fatty degeneration to non-alcoholic steatohepatitis, so that some eventually develop into cirrhosis of the liver, and even evolve into hepatocellular carcinoma. In recent years, with the increasing incidence of obesity, the incidence of non-alcoholic fatty liver disease has increased year by year. Therefore, it is of great significance to seek an effective drug for the treatment of non-alcoholic fatty liver disease. [0003] There are currently no drugs approved to treat nonalcoholic hepatitis. Trip...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/585A61P1/16A61K36/37
CPCA61K31/585A61P1/16A61K36/37
Inventor 黄蓉双
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com